What is EdiGene?
Founded in 2015 and headquartered in Beijing, China, EdiGene is at the forefront of leveraging advanced genome editing technologies to accelerate drug discovery. The company's focus lies in developing innovative therapeutics aimed at addressing a broad spectrum of genetic diseases and oncological conditions. EdiGene's commitment to cutting-edge science positions it as a key player in the rapidly evolving biotechnology landscape.
How much funding has EdiGene raised?
EdiGene has raised a total of $154.5M across 3 funding rounds:
Series A
$14.5M
Other Financing Round
$11M
Series B
$129M
Series A (2018): $14.5M with participation from Huagai Capital, Lilly Asia Ventures, WI Harper Group, and IDG
Other Financing Round (2019): $11M led by Lilly Asia Ventures and IDG Capital Partners
Series B (2021): $129M supported by Kunlun Capital, Lilly Asia Ventures, Sequoia Capital, BioTrack Capital, Loyal Valley Capital, Huagai Capital, 3H Health Investment, IDG Capital Partners, Alwin Capital, and Sherpa Healthcare Partners
Key Investors in EdiGene
Lilly Asia Ventures
Lilly Asia Ventures is a leading biomedical venture capital firm focused on partnering with entrepreneurs to build companies developing breakthrough products for human health.
IDG Capital Partners
IDG Capital is an investment firm specializing in private equity, venture capital, and mergers and acquisitions, with a focus on developing companies.
Huagai Capital
Huagai Capital operates in the Investment Banking industry, focusing on providing capital and strategic support to companies.
What's next for EdiGene?
The substantial enterprise-level backing and recent strategic investment signal a pivotal growth phase for EdiGene. This influx of capital is expected to fuel further research and development, potentially accelerating the clinical translation of its genome editing-based therapies. The company is poised to expand its therapeutic pipeline and solidify its market position in the competitive biotech sector, aiming to bring life-changing treatments to patients worldwide.
See full EdiGene company page
